Libyom Microbiome New Drug Selected as a New Project for National New Drug Development

Inflammatory Bowel Disease Microbial Gene Therapy 'LIV001'
Research and Development Funding Supported for 2 Years

LivBiome, a microbiome-based new drug development company, announced on the 4th that it has been selected as a new project in the National New Drug Development Project led by the National New Drug Development Project Group and has signed an agreement. LivBiome is an affiliate of Medytox.

Libyom CI. [Image provided by Libyom]

LivBiome's 'LIV001', selected as a new project, is a microbiome therapeutic (Live Biotherapeutic Products·LBP) that uses live microorganisms as therapeutic agents. Using the patented microbial engineering platform eLBP technology, the gene for VIP (Vasoactive intestinal peptide), an immunomodulatory peptide, is introduced into microorganisms to enhance therapeutic effects against immune diseases.

According to LivBiome, microbiome therapeutics developed based on recombinant gene technology can design and produce microorganisms according to the desired mechanism of action, thereby improving therapeutic efficacy and drug properties, making it a technology that overcomes the limitations of existing microbiome therapeutics. They also added that the anti-inflammatory effects and safety have been demonstrated through animal models, and global clinical development is being pursued targeting Australia, Europe, and the United States.

Kim Young-hyun, head of research at LivBiome, said, "With the selection of this project, we will receive research and development funding necessary for preclinical studies and clinical trial drug production of LIV001 over the next two years," emphasizing, "This will accelerate global clinical progress and increase the likelihood of new drug success."

Song Ji-yoon, CEO of LivBiome, stated, "Starting with LIV001, LivBiome plans to expand its pipeline applying eLBP technology to various intractable diseases such as solid tumors and transplant diseases and proceed with clinical development, thereby proving the potential and business feasibility of microbial gene therapy new drugs."

The National New Drug Development Project is a government-wide national research and development (R&D) support project that selects excellent new drug development projects targeting pharmaceutical and bio companies as well as industry-academia-research institutes to strengthen global competitiveness in domestic new drug development and promote public health, supporting all stages of the development process.

This content was produced with the assistance of AI translation services.